Definition and epidemiology
Acute radiation syndrome is the acute illness caused by whole-body or significant partial-body irradiation with a high absorbed dose (typically >0.7 Gy) delivered over a short time, usually minutes to hours. ARS is distinguished from chronic low-dose radiation exposure and localized radiation injury.
True ARS is rare. Cases occur primarily in nuclear reactor accidents (Chernobyl 1986, Fukushima 2011), industrial radiography accidents, criticality accidents in nuclear facilities, and rarely from radiotherapy errors or malicious radiological exposure. The global incidence is fewer than 500 documented cases since 1945. Most exposures occur in occupational settings among male workers aged 20-50 years. Military personnel and emergency responders at radiological incidents are also at risk.
- Time to vomiting predicts dose: <30 min suggests >6 Gy, >2 hours suggests <2 Gy
- Absolute lymphocyte count at 48 hours is the best early biological dosimeter
- ARS has four phases: prodromal, latent, manifest illness, recovery or death
- Hematopoietic syndrome (0.7-10 Gy) causes pancytopenia with nadir at 2-4 weeks; infection and hemorrhage are main threats
- G-CSF or GM-CSF should be started within 24-48 hours for doses >2 Gy to accelerate neutrophil recovery
- Stem cell transplant is considered for doses >7-8 Gy but has high mortality; use irradiated blood products to prevent GVHD
- Gastrointestinal syndrome (>10 Gy) and CNS syndrome (>50 Gy) are uniformly fatal
- Long-term survivors have 2-5 times increased risk of secondary malignancies and cataracts
Etiology and risk factors
ARS results from exposure to penetrating ionizing radiation—gamma rays, X-rays, or neutrons—that deposits energy throughout the body. Alpha and beta particles cause primarily localized skin injury unless internalized.
Risk factors and exposure scenarios:
- Nuclear reactor accidents with breach of containment
- Criticality accidents in fuel processing or weapons facilities
- Industrial radiography source mishandling (lost or abandoned sources)
- Radiotherapy equipment malfunction or calculation errors
- Improvised nuclear devices or radiological dispersal devices ("dirty bombs")
- Occupational exposure without adequate shielding or monitoring
- Proximity to unshielded high-activity sources
The severity depends on total absorbed dose, dose rate, type of radiation, and body distribution. Whole-body exposure is more dangerous than partial-body. Higher dose rates (acute exposure) cause more severe injury than the same total dose delivered over weeks.
Pathophysiology
Ionizing radiation directly damages DNA and generates reactive oxygen species, causing cell death, particularly in rapidly dividing tissues. Radiosensitivity follows the Bergonié-Tribondeau law: cells are most sensitive when they are actively dividing, have long mitotic futures, and are undifferentiated.
Dose-dependent syndromes:
- Hematopoietic syndrome (0.7-10 Gy): Bone marrow stem cell depletion leads to pancytopenia. Lymphocytes drop within hours; neutrophils and platelets decline over 2-3 weeks. Infection and hemorrhage are the main causes of death at 2-8 weeks.
- Gastrointestinal syndrome (>10 Gy): Crypt stem cell destruction leads to villous denudation, loss of mucosal barrier, fluid/electrolyte loss, bacterial translocation, and sepsis. Death occurs at 3-10 days.
- Cardiovascular/CNS syndrome (>50 Gy): Direct vascular and neuronal injury causes cerebral edema, seizures, hypotension, and death within 24-48 hours. This dose is uniformly fatal.
Radiation also triggers a systemic inflammatory response with cytokine release, endothelial injury, and multiorgan dysfunction. The skin receives injury at all doses, with acute erythema and later desquamation or necrosis.
Clinical features
ARS unfolds in four classic phases:
Prodromal phase (0-2 days)
Occurs within minutes to hours of exposure. Severity and rapidity correlate with dose.
- Nausea and vomiting (earliest and most consistent symptom)
- Anorexia, fatigue, malaise
- Diarrhea (with higher doses)
- Headache, fever
- Hypotension and tachycardia (very high doses)
Time to emesis is prognostic: <30 minutes suggests >6 Gy; >2 hours suggests <2 Gy.
Latent phase (1-6 weeks)
Patients feel relatively well. Duration inversely correlates with dose. Absent or very short at high doses. Lymphocyte count begins declining.
Manifest illness phase (weeks 2-8)
Symptoms depend on the predominant syndrome:
Hematopoietic (most common):
- Progressive pancytopenia
- Infections: fever, sepsis (often from gut flora)
- Hemorrhage: petechiae, ecchymoses, mucosal bleeding
- Anemia: fatigue, pallor
- Oral mucositis, esophagitis
Gastrointestinal:
- Severe bloody diarrhea
- Intractable nausea and vomiting
- Abdominal pain and distension
- Dehydration and electrolyte imbalance
- Septic shock from bacterial translocation
Cutaneous (overlaps all doses):
- Early transient erythema (24-48 hours)
- Delayed erythema (week 2-3)
- Dry or moist desquamation
- Epilation (hair loss at ~3 Gy)
- Necrosis and ulceration at high doses
Recovery or death
With hematopoietic syndrome, recovery begins at 4-8 weeks if the patient survives infections and bleeding. Gastrointestinal and CNS syndromes are usually fatal despite intensive care.
Diagnosis
Diagnosis is clinical, based on exposure history and characteristic temporal pattern. Absolute lymphocyte count (ALC) is the most useful early biomarker.
Initial assessment:
- Detailed exposure history: time, duration, source type, distance, shielding
- Time to onset of vomiting (most predictive symptom)
- Serial complete blood counts with differential every 4-6 hours initially
- Baseline chemistry, liver and renal function
- HLA typing and ABO blood group for potential transplant
Dosimetry estimation:
- Physical dosimetry: personal dosimeters, environmental monitoring
- Biological dosimetry: lymphocyte depletion kinetics, dicentric chromosome analysis (gold standard), micronuclei assay, and newer assays (gene expression, EPR)
- Clinical dosimetry: time to emesis, prodromal severity
Lymphocyte count thresholds (24-48 hours post-exposure):
| ALC (cells/mm³) | Estimated dose | Prognosis |
|---|---|---|
| >1200 | <2 Gy | Minimal syndrome |
| 800-1200 | 2-4 Gy | Moderate |
| 500-800 | 4-6 Gy | Severe |
| 100-500 | 6-8 Gy | Critical |
| <100 | >8 Gy | Lethal without transplant |
Ongoing monitoring:
- Serial CBCs: nadir typically at 2-4 weeks
- Blood cultures if febrile
- Imaging for complications (pneumonia, typhlitis)
- Cytogenetic analysis for dose confirmation (not immediately available)
Differential considerations:
Rule out trauma, burns, chemical exposure, and blast injury in mass casualty scenarios. Combined injury (radiation plus trauma or burns) worsens prognosis significantly.
Differential diagnosis
The prodromal phase mimics many acute illnesses:
- Acute gastroenteritis: Viral or bacterial; no latent phase, normal CBC
- Food poisoning: Abrupt onset, epidemiological link, resolves quickly
- Chemical toxicity: Heavy metals, organophosphates; distinct exposure history
- Sepsis: Positive cultures, no latent phase, responds to antibiotics
- Bone marrow failure syndromes: Aplastic anemia, myelodysplasia; chronic onset, no prodrome
- Chemotherapy toxicity: Known treatment history, expected cytopenias
- Acute leukemia: Blasts on peripheral smear, organomegaly
- Viral hemorrhagic fevers: Endemic areas, person-to-person spread, no latent phase
- Thrombotic thrombocytopenic purpura: Schistocytes, renal failure, neurologic symptoms
Key discriminators are the exposure history, characteristic temporal pattern with latent phase, and rapid absolute lymphocyte depletion within 24-48 hours.
Management
No specific antidote exists. Management is intensive supportive care, prevention of infection and bleeding, and hematopoietic support. Initiate treatment before dose estimates are final.
Acute phase (first 24-48 hours)
Decontamination:
- Remove clothing (eliminates 90% of external contamination)
- Wash skin and hair with soap and water
- Survey for residual contamination with Geiger counter
- Treat life-threatening trauma first (ABCs)
Supportive care:
- IV fluids for hydration
- Antiemetics: ondansetron, granisetron
- Analgesics
- Anxiolytics as needed
Baseline labs and dose estimation as described above.
Hematopoietic support (for doses 2-10 Gy)
Growth factors (start within 24-48 hours):
- G-CSF (filgrastim) or GM-CSF (sargramostim) to accelerate neutrophil recovery
- Evidence supports use even in mild exposures
Hematopoietic stem cell transplantation:
- Consider for doses >7-8 Gy with severe marrow aplasia
- HLA-matched allogeneic transplant from sibling or unrelated donor
- Controversial: high transplant-related mortality, spontaneous recovery possible at 6-8 Gy
- Best outcomes when performed at specialized centers within 1-3 weeks
Infection prevention and treatment
- Protective isolation, HEPA filtration
- Broad-spectrum antibiotics at first fever or when ANC <500 (cefepime, meropenem, or piperacillin-tazobactam)
- Add antifungals if prolonged neutropenia (fluconazole prophylaxis; amphotericin or voriconazole for invasive disease)
- Antivirals: acyclovir for HSV/VZV reactivation
- Avoid intramuscular injections
- Oral non-absorbable antibiotics for gut decontamination (controversial)
Transfusion support
- Leukocyte-depleted, irradiated blood products to prevent GVHD and CMV transmission
- Platelet transfusions for counts <10,000 or bleeding
- Packed red cells for symptomatic anemia
Gastrointestinal support
- NPO if severe GI syndrome
- Total parenteral nutrition
- Octreotide for secretory diarrhea
- Aggressive fluid and electrolyte replacement
Cutaneous care
- Gentle wound care, topical antibiotics
- Silver sulfadiazine or modern dressings for desquamation
- Surgical debridement for necrotic tissue
- Skin grafting may be required for deep ulcers
Investigational therapies
- Cytokine cocktails (IL-11, thrombopoietin analogs)
- Radioprotectants if given before or immediately after exposure (amifostine, Prussian blue for internal contamination with cesium or thallium)
- Chelating agents for internal contamination: DTPA for transuranics, Prussian blue for cesium
Psychological support
Anxiety, depression, and PTSD are common. Provide counseling and psychiatric care.
Long-term follow-up
Survivors require lifelong monitoring for cataracts, secondary malignancies, chronic organ dysfunction, and reproductive effects.
Complications and prognosis
Acute complications:
- Sepsis and septic shock (most common cause of death)
- Hemorrhage (GI, pulmonary, CNS)
- Acute respiratory distress syndrome
- Multiorgan failure
- Typhlitis (neutropenic enterocolitis)
- Skin necrosis and secondary infections
Delayed and chronic complications:
- Malignancies: Leukemia, thyroid cancer, breast cancer, lung cancer; latency 5-20 years
- Cataracts: Occur after doses >2 Gy; latency 1-10 years
- Infertility: Temporary at 2-3 Gy, permanent at >6 Gy for testes, >4 Gy for ovaries
- Growth retardation in children
- Hypothyroidism
- Cardiovascular disease: Accelerated atherosclerosis, pericarditis
- Pulmonary fibrosis (if lungs heavily exposed)
- Chronic bone marrow dysfunction
- Neurologic sequelae: Cognitive impairment, peripheral neuropathy
- Chronic skin changes: Fibrosis, telangiectasias, chronic ulcers
Prognosis:
Prognosis depends on absorbed dose, dose rate, and quality of care.
| Dose (Gy) | Syndrome | Mortality without treatment | Mortality with treatment |
|---|---|---|---|
| <1 | Subclinical | 0% | 0% |
| 1-2 | Mild hematopoietic | 0-10% | 0% |
| 2-4 | Moderate hematopoietic | 20-50% | <5% |
| 4-6 | Severe hematopoietic | 50-90% | 10-50% |
| 6-8 | Very severe | >90% | 50-90% |
| 8-10 | Hematopoietic + GI | ~100% | 80-100% |
| >10 | GI syndrome | 100% | 100% |
| >50 | CNS syndrome | 100% | 100% |
With modern intensive care and hematopoietic growth factors, survival has improved significantly for doses in the 2-6 Gy range. Doses above 8 Gy are often fatal despite transplant. Combined injury (radiation plus trauma or burns) significantly worsens prognosis, lowering the LD50 by approximately 1-2 Gy.
Survivors have good functional recovery but face lifelong cancer risk approximately 2-5 times that of the general population.
VOMIT predicts severe ARS: Vomiting within 1 hour, Onset rapid, More than 4 Gy likely, Immediate treatment needed, Transplant may be required.
Practice questions
1. A 34-year-old male radiation worker presents to the emergency department 4 hours after an industrial radiography accident. He reports sudden onset of nausea and vomited twice within the first 30 minutes. He now feels weak and fatigued but denies diarrhea. Vital signs are normal. Physical examination is unremarkable. Laboratory studies show WBC 8,200/mm³, hemoglobin 14.5 g/dL, and platelets 210,000/mm³. Absolute lymphocyte count is 900/mm³. Which of the following is the most appropriate next step in management?
2. A 28-year-old woman is brought to the hospital 6 days after a nuclear reactor accident. She initially had severe nausea and vomiting within 1 hour of exposure, followed by 4 days where she felt relatively well. She now presents with fever to 39°C (102.2°F), severe watery diarrhea with blood, and abdominal cramping. Physical examination shows diffuse abdominal tenderness and dry mucous membranes. Labs show WBC 1,200/mm³ with absolute neutrophil count 200/mm³, hemoglobin 10.2 g/dL, and platelets 45,000/mm³. Which of the following best explains this patient's current presentation?
3. A 45-year-old male survivor of a radiation accident 18 days ago is admitted with fever, chills, and fatigue. He initially received 5 Gy whole-body exposure and has been treated with G-CSF since day 1. Current labs show WBC 600/mm³, absolute neutrophil count 100/mm³, hemoglobin 7.8 g/dL, and platelets 8,000/mm³. Blood cultures are pending. Which of the following is the most appropriate immediate management?
Frequently asked questions
What causes acute radiation syndrome?
Acute radiation syndrome is caused by exposure to a high dose of penetrating ionizing radiation (gamma rays, X-rays, or neutrons) delivered to a large portion of the body over a short time, typically minutes to hours. Common scenarios include nuclear reactor accidents, industrial radiography accidents, criticality events in nuclear facilities, and rarely radiotherapy equipment malfunctions. The radiation damages rapidly dividing cells, especially in bone marrow and gastrointestinal tract, leading to systemic illness. The severity depends on total dose, dose rate, radiation type, and body area exposed.
What are the first symptoms of acute radiation syndrome?
The first symptoms appear within minutes to hours and include nausea and vomiting (the earliest and most consistent sign), loss of appetite, fatigue, and malaise. At higher doses, diarrhea, headache, and fever also occur. This prodromal phase lasts hours to 2 days, followed by a latent period where patients feel relatively well before the main illness develops at 1-6 weeks. Time to onset of vomiting is prognostic: vomiting within 30 minutes suggests a very high, potentially lethal dose.
How is acute radiation syndrome diagnosed?
Diagnosis is based on exposure history and characteristic clinical pattern. The absolute lymphocyte count measured at 24-48 hours post-exposure is the most useful early biological marker; rapid lymphocyte depletion indicates significant exposure. Serial complete blood counts every 4-6 hours initially help estimate dose. The time to vomiting onset also predicts severity. Confirmatory tests include dicentric chromosome analysis (gold standard biodosimetry) and physical dosimetry from personal dosimeters or environmental monitoring. HLA typing is done early if transplant may be needed.
Is acute radiation syndrome curable?
ARS at moderate doses (2-6 Gy) is survivable with intensive supportive care including growth factors, antibiotics, transfusions, and isolation to prevent infection. Modern treatment has improved survival significantly in this range. At very high doses causing gastrointestinal syndrome (>10 Gy) or CNS syndrome (>50 Gy), ARS is uniformly fatal despite all interventions. Stem cell transplantation may save some patients with severe marrow damage (6-10 Gy) but carries high risks. Survivors face long-term complications including cancer risk and require lifelong monitoring.
Acute radiation syndrome vs chronic radiation exposure — what is the difference?
Acute radiation syndrome occurs after a high dose of radiation delivered over a short time (minutes to hours), causing immediate systemic illness with prodromal symptoms, latent phase, and then bone marrow failure or gastrointestinal injury within weeks. Chronic radiation exposure involves repeated low doses over months to years, which does not cause ARS but increases long-term cancer risk, cataracts, and organ damage without the acute phases. The key difference is dose rate and timing: ARS is a medical emergency from sudden high exposure, while chronic exposure causes delayed effects without acute illness.
Key drugs
Related conditions and differentials
Sources and further reading
StatPearls (NCBI Bookshelf)MedlinePlusWHO ICD-10: T66
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.